Skip to content

Regencell Bioscience

US · RGC #2393 by market cap Listed 2021
4.18 -0.18 -4.13%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:34

Revenue annual, last 8 years

Income statement

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Revenue ----------------
Gross profit ----------------
Selling & admin expenses 162.77K426.14K943.04K5.11M4.69M3.67M2.82M10.42M
Research & development 228.22K386.23K438.32K2.51M1.58M1.07M948.29K1.30M
Operating profit -390.99K-812.37K-1.38M-7.62M-6.27M-4.74M-3.77M-11.72M
Pretax profit -390.99K-812.37K-1.35M-7.59M-6.06M-4.36M-3.58M-11.70M
Tax 00000000
Net profit -390.99K-812.37K-1.35M-7.59M-6.06M-4.36M-3.58M-11.70M
Basic EPS 00000000
Diluted EPS 0.000.000.00-0.02-0.01-0.01-0.01-0.02

Balance sheet

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Total current assets 243.31K386.98K66.85K16.44M11.62M8.11M4.90M14.22M
Cash & ST investments 243.31K386.98K59.41K16.42M11.56M7.96M4.90M14.19M
Inventory ----------------
Total assets 243.31K514.02K340.13K18.02M12.62M8.44M5.76M14.73M
Total current liabilities 2.08M3.16M4.34M577.76K606.91K193.58K663.67K1.32M
Short-term debt 2.08M3.07M3.68M410.99K438.26K59.81K312.78K236.31K
Long-term debt ----------------
Total liabilities 2,081,828.003,164,910.004,337,771.00938,032.00632,320.00219,512.00895,308.001,380,194.00
Total equity -1.84M-2.65M-4.00M17.08M11.99M8.22M4.86M13.35M
Retained earnings -1.84M-2.65M-4.00M-11.44M-17.32M-21.62M-25.20M-36.90M

Cash flow

Line item 2019 2020 2021 2022 2023 2024 2025 2026
Operating cash flow -390.99K-726.57K-767.31K-5.27M-4.96M-4.00M-3.11M-7.70M
Depreciation & amortization 09.52K26.46K604.40K769.69K745.59K392.74K404.54K
Free cash flow -390.99K-844.41K-767.31K-6.05M-4.99M-4.01M-3.27M-7.70M
Dividends paid ----------------
Stock buybacks / issuance --0022.67M--0018.62M
Ending cash balance 243.31K386.98K59.41K6.42M1.56M2.96M2.42M14.19M

Returns & efficiency

Line item 2019 2020 2021 2022 2023 2024 2025 2026
ROE % -------113.96-40.36-42.49-54.81-128.52
ROA % -160.70-214.54-315.34-81.11-38.32-40.85-50.50-114.25
ROIC % -------83.28-38.71-41.37-52.29-122.86
5-year avg ROE % ---------------76.03
EBIT margin % ----------------
FCF / sales % ----------------
Current ratio 0.120.120.0228.4619.1541.927.3910.77
Quick ratio 0.120.120.0228.4619.1541.927.3910.77
Debt / assets 855.64597.241,082.514.283.671.029.462.01
LT debt / equity ------2.110.210.324.770.45
Interest coverage ----------------
Revenue CAGR (3Y) % ------0.000.000.000.000.00
Net income CAGR (3Y) % ----------------
FCF CAGR (3Y) % ----------------

Quote time 2026-11-20 19:34:41 · For reference only, not investment advice and not tailored to your situation.

Regencell Bioscience discussion 0 comments

Add a comment